Beyond the Snapshot: When Repeated Measurements Improve Aging-Biomarker Evidence
When repeated measurements strengthen aging-biomarker evidence—and how assay noise, missing follow-up and endpoint limits constrain interpretation.
LongevityNext
Research Notes and Articles
Longevity Capital in 2026: Disclosed Deals, Different Instruments, and the Limits of the Evidence
Nine disclosed 2026 transactions show different instruments and business models—not a measure of total longevity investment or clinical validation.
GLP-1 Therapies and Longevity Claims: What Human Outcomes Support—and What Remains Untested
Separates molecule-specific clinical outcomes from observational, mechanistic and direct longevity claims.